Amlodipine, Lisinopril, Rosuvastatin
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Equamer® is indicated as a replacement therapy in adult patients, whose condition is adequately controlled by using amlodipine, lisinopril and rosuvastatin in the same doses as Ekmeamer® for the treatment of arterial hypertension and concomitant dyslipidemia: - primary hypercholesterolemia (type IIa by Fredrickson classification , with the exception of familial heterozygous hypercholesterolemia) or mixed hypercholesterolemia (type IIb according to Fredrickson's classification), when diet and other non-drug methods (for example , exercise, weight loss) are insufficient; - familial homozygous hypercholesterolemia, when a diet or other lipid-lowering therapy (for example, LDL-apheresis) is not effective enough; - hypertriglyceridemia (type IV according to Fredrickson's classification).
Equamer is indicated as a replacement therapy in adult patients, whose condition is already adequately controlled by taking amlodipine, lisinopril and uzuvastatin in the same doses as in the preparation Equamer, in the treatment of hypertension and concomitant dyslipidemia:
- primary hypercholesterolemia (Pa type according to Fredrickson classification, with the exception of familial heterozygous hypercholesrhythmia) or mixed hypercholesterolemia (Po type according to Fredrickson classification) when diet and other non-drug methods (for example, exercise, weight loss) are insufficient;
- familial homozygous hypercholesterolemia, when diet or other lipid-lowering therapy (for example, LDL-apheresis) is not effective enough;
- hypertriglyceridemia (type IV according to Fredrickson's classification).
- active substances: amlodipine besylate - 13.88 mg (equivalent to amlodipine 0 mg), lisinopril dihydrate - 21.76 mg (equivalent to lysinonryl 20 mg), rosuvastatin calcium - 10.4 mg (equivalent to rosuvastatin 10 mg);
- excipients: microcrystalline cellulose, type 12 - 94.82 mg, microcrystalline cellulose, type 101 - 90.54 mg, lactose monohydrate - 48.1 mg, carboxymethyl starch sodium - 11 mg, magnesium hydroxide - 7.5 mg, magnesium stearate - 3 mg, Opadray II yellow - 2 mg (contains: polyvinyl alcohol 40.0%), titanium dioxide 23.5%, macrogol-3350 20.2%>, talcum 14.8%, iron dye yellow oxide 1.5% , hard gelatin capsule - 76 mg (contains: azorubine dye 0.0882%, indigo carmine), 0284%, guitar dioxide 2.2056%, gelatin up to 100%).
No customer reviews for the moment.
Patients with liver failure: there is no experience of using rosuvastatin in patients with a score above 9 on the Child-Pyo scale (see the Pharmacokinetics section).
Aortic stenosis, mitral stenosis, hypertrophic obstructive sardiomyopathy, hypotension, pandemic diseases, including cerebrovascular diseases, including cerebrovascular insufficiency), coronary heart disease, coronary hemorrhagicity, CHF of a nasismatic etiology, class-16 within 1 month after it), stabilization of stenocardia, sick sinus syndrome (severe tachycardia or bradycardia), severe autoimmune systemic diseases of the connective th tissue (including systemic lupus erythematosus, scleroderma), inhibition of bone marrow soretvorepiya, diabetes mellitus, hyperkalemia, bilateral renal artery stenosis, tenosity of a single kidney artery, condition after kidney transplantation, renal insufficiency of mild to moderate severity (CC 30- 80 ml / min), azotemia, levorchyi aldosteronism, diet with restriction of table salt, conditions,: supported by a decrease in the volume of circulating blood (including vomiting, diarrhea), old age, mild liver failure (5-6 points on the Child-Pyo scale) and moderate severity (7-9 points on the Child-Pyo scale), hypothyroidism, personal or family history of hereditary muscular diseases and previous history of muscle toxicity with the use of other inhibitors of MG-CoA reductase or fibrates, alcohol abuse, conditions in which this increase in plasma concentration of rosuvastatin, raciality is a Mongoloid race), simultaneous administration of fibrates, bolevaniya liver history, sepsis, extensive surgery, trauma, severe metabolic, shdokrinnye or water-electrolyte disorders, or uncontrolled seizure 1ripadki.
Pregnancy and Lactation
Taking the drug Equamer is contraindicated during pregnancy. Adequate strictly controlled clinical studies on the effect of fsparata Equamer during pregnancy have not been conducted.
Acceptance of ACE inhibitors in the second and third trimesters of pregnancy can cause: the death of the fetus and the newborn. Perhaps the development of oligohydramnios during pregnancy, as well as hypoplasia of the bones of the skull, deformation of the bones of the skull and face, lung hypoplasia and impaired development of the kidneys in the newborn.
Since cholesterol and other cholesterol biosynthesis products are important for the development of the fetus, the potential risk of inhibition of HMG-CoA reductase exceeds the benefit of rosuvastatin during pregnancy.
Women of reproductive age should use adequate methods of contraception. In the event of pregnancy in the course of therapy, the drug should be immediately discontinued and, if necessary, alternative treatment should be prescribed.
Do not start therapy with Equamer during pregnancy. When planning a pregnancy, it is necessary to switch to an alternative therapy with a proven safety profile during pregnancy.Breastfeeding period
The use of the drug Equamer is contraindicated during breastfeeding. It is not known whether the active ingredients are excreted into breast milk. It is known that they penetrate into the milk of lactating rats. If necessary, the use of the drug during lactation breastfeeding should be stopped.Fertility
Adequate strictly controlled clinical studies on the effect of Equamer on fernlyuyust were not conducted.
Data on drug overdose Equamer are not available.
Symptoms: marked reduction in blood pressure with the possible development of reflex tachycardia and excessive peripheral vasodilation (the risk of severe and persistent arterial gynotension, including the development of shock and death).
Treatment: gastric lavage, the appointment of Activated charcoal (especially in the first 2 hours after overdose), maintaining the function of the cardiovascular system, the elevated position of the lower extremities, control functions of the cardiovascular and respiratory systems, control of circulating blood volume (BCC) and diuresis. To restore vascular tone - the use of vasoconstrictor agents (in the absence of contraindications to their use); To eliminate the effects of calcium channel blockade, intravenous calcium gluconate is administered. Hemodialysis is ineffective.
Symptoms: marked decrease in blood pressure, dry mouth, drowsiness, urinary retention, constipation, anxiety, irritability, renal dysfunction, water and electrolyte balance, tachycardia, bradycardia, collapse, hyperventilation of the lungs, dizziness.
Treatment: symptomatic therapy, intravenous administration of a 0.9% solution of sodium chloride and, if possible, the use of vazoiressors, control of blood pressure, water-oligo balance. With sustainable bradycardia, an artificial pacemaker can be set. Hemodialysis may be used (see instructions for patients on hemodialysis in the section "Special Instructions").
When several daily doses are taken simultaneously, the pharmacokinetic parameters of rosuvastatin do not change.
There is no specific treatment for an overdose of rosuvastatin. In case of overdose, it is recommended to carry out symptomatic treatment and measures aimed at maintaining the functions of vital organs and systems. Control of liver function and CPK activity is required. It is unlikely that hemodialysis will be effective.
- Brand name: Equamer
- Active ingredient: Amlodipine, Lisinopril, Rosuvastatin
- Dosage form: Capsules
- Manufacturer: Gedeon Richter
- Country of Origin: Hungary